- Home
- IMCR
as 01-17-2025 4:00pm EST
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | OXFORDSHIRE |
| Market Cap: | 1.5B | IPO Year: | 2021 |
| Target Price: | $65.18 | AVG Volume (30 days): | 323.9K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.69 - $76.98 | Next Earning Date: | 02-26-2025 |
| Revenue: | $296,312,000 | Revenue Growth: | 25.09% |
| Revenue Growth (this year): | 28.91% | Revenue Growth (next year): | 12.65% |
Latest Immunocore Holdings plc News
IMCR Breaking Stock News: Dive into IMCR Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
GlobeNewswire
9 days ago
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
13 days ago
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
17 days ago
Immunocore Names Travis Coy Chief Financial Officer
GlobeNewswire
17 days ago
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
MT Newswires
a month ago
Immunocore Doses First Patient in Phase 1 Trial of Potential Cancer Treatment
GlobeNewswire
a month ago
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Clinical Trials Arena
a month ago
Immunocore doses first subject in gastrointestinal cancer therapy trial
Compare IMCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMCR Immunocore Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.